{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:22:16Z","timestamp":1767068536541,"version":"3.48.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2021-04"],"award-info":[{"award-number":["WE.03-2021-04"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Neuroinflammation plays a key role in Alzheimer\u2019s disease (AD) pathophysiology, but it is not clear how neuroinflammation contributes to disease progression. We aim to investigate the role of neuroinflammation on longitudinal cognition and survival in a unique cohort with PET imaging of translocator protein (TSPO) binding tracer [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 and long-term follow-up. We hypothesized that higher [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 binding would be associated with faster cognitive decline and higher mortality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      19 participants with AD dementia, 9 participants with MCI due to AD, and 21 healthy controls (HC) with historical dynamic [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 PET data were included. Principal component analysis was performed to identify relevant [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 patterns. An additional AD ROI consisting of temporal and parietal regions was investigated. [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 scores in the principal components (PCs) and AD ROI were compared between groups using ANOVA. Longitudinal MMSE covering a period up to 11 years was used to measure cognitive decline. We used linear mixed models with random subject-specific intercepts and slopes corrected for age, sex and syndrome diagnosis to investigate the association of neuroinflammation with cognition in MCI and AD. Survival data were available for all MCI and AD participants, up to 15.7 years after PET. To examine the influence of neuroinflammation on survival time, we used age, sex, and syndrome diagnosis adjusted cox proportional-hazards models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two PCs were retained. PC1 explained 55.4% of the variance and was most explained by [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 binding in the thalamus and entorhinal cortex. PC2 explained 15.3% of the variance and constituted of mostly the entorhinal cortex. There was no difference in [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 PET between AD, MCI and HCs (range F(2)\u2009=\u20090.157\u20131.231,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.3). [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 did not predict longitudinal MMSE (PC1: \u03b2\u2009=\u20090.02,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.73; PC2: \u03b2\u2009=\u20090.1,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.44; AD ROI: \u03b2\u2009=\u20091.3,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.57) or survival (PC1: HR\u2009=\u20090.90[95%CI: 0.80, 1.03],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.13; PC2: HR\u2009=\u20090.96[0.75, 1.23],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.72; AD ROI: HR\u2009=\u20090.02[0.00, 1.33],\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Contrary to our hypothesis, we did not find evidence for [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 PET predicting long-term cognitive decline or survival. This may indicate that the level of [\n                      <jats:sup>11<\/jats:sup>\n                      C]PK11195 PET binding earlier in the disease trajectory is not directly linked to the long-term outcome.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-025-01915-3","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T02:35:57Z","timestamp":1763778957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroinflammation PET and long-term cognition and survival in symptomatic Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"given":"Roos M.","family":"Rikken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maqsood","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma M.","family":"Coomans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"van der Vlies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.","family":"Windhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolande A.L.","family":"Pijnenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Everard G.B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsmarieke","family":"van de Giessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"2","key":"1915_CR1","doi-asserted-by":"publisher","first-page":"e12385","DOI":"10.1002\/trc2.12385","volume":"9","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Alzheimer\u2019s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9(2):e12385.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"1915_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P. Neuroinflammation and microglial activation in alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157\u201372.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"1915_CR3","first-page":"792","volume":"140","author":"Z Fan","year":"2017","unstructured":"Fan Z, et al. An early and late peak in microglial activation in alzheimer\u2019s disease trajectory. Brain. 2017;140(3):792\u2013803.","journal-title":"Brain"},{"key":"1915_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arr.2019.01.002","volume":"50","author":"S Bradburn","year":"2019","unstructured":"Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and alzheimer\u2019s disease: A meta-analysis. Ageing Res Rev. 2019;50:1\u20138.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"1915_CR5","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/alz.13699","volume":"20","author":"SM Rossano","year":"2024","unstructured":"Rossano SM, et al. Microglia measured by TSPO PET are associated with alzheimer\u2019s disease pathology and mediate key steps in a disease progression model. Alzheimers Dement. 2024;20(4):2397\u2013407.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"1915_CR6","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, et al. Microglial activation and Tau propagate jointly across Braak stages. Nat Med. 2021;27(9):1592\u20139.","journal-title":"Nat Med"},{"key":"1915_CR7","doi-asserted-by":"crossref","unstructured":"Passamonti L et al. [11C]PK11195 binding in alzheimer disease and progressive supranuclear palsy. Neurology, 2018. 90(22): p. e1989-e1996.","DOI":"10.1212\/WNL.0000000000005610"},{"key":"1915_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2019.09.019","volume":"85","author":"J Zou","year":"2020","unstructured":"Zou J, et al. Microglial activation, but not Tau pathology, is independently associated with amyloid positivity and memory impairment. Neurobiol Aging. 2020;85:11\u201321.","journal-title":"Neurobiol Aging"},{"issue":"5","key":"1915_CR9","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/brain\/awaa088","volume":"143","author":"M Malpetti","year":"2020","unstructured":"Malpetti M, et al. Microglial activation and Tau burden predict cognitive decline in alzheimer\u2019s disease. Brain. 2020;143(5):1588\u2013602.","journal-title":"Brain"},{"key":"1915_CR10","doi-asserted-by":"crossref","unstructured":"Wang Q, et al. Baseline microglial activation correlates with brain amyloidosis and longitudinal cognitive decline in alzheimer disease. Neurol Neuroimmunol Neuroinflamm. 2022;9(3).\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35260470\/.","DOI":"10.1212\/NXI.0000000000001152"},{"key":"1915_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.bbi.2023.08.027","volume":"114","author":"F Yasuno","year":"2023","unstructured":"Yasuno F, et al. Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with alzheimer\u2019s disease. Brain Behav Immun. 2023;114:214\u201320.","journal-title":"Brain Behav Immun"},{"issue":"6","key":"1915_CR12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/brain\/awy079","volume":"141","author":"L Hamelin","year":"2018","unstructured":"Hamelin L, et al. Distinct dynamic profiles of microglial activation are associated with progression of alzheimer\u2019s disease. Brain. 2018;141(6):1855\u201370.","journal-title":"Brain"},{"issue":"12","key":"1915_CR13","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s43587-022-00310-z","volume":"2","author":"JB Pereira","year":"2022","unstructured":"Pereira JB, et al. Microglial activation protects against accumulation of Tau aggregates in nondemented individuals with underlying alzheimer\u2019s disease pathology. Nat Aging. 2022;2(12):1138\u201344.","journal-title":"Nat Aging"},{"issue":"1","key":"1915_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jnnp-2020-323894","volume":"92","author":"A Low","year":"2020","unstructured":"Low A, et al. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2020;92(1):45\u201352.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1915_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neurobiolaging.2020.10.029","volume":"98","author":"A Low","year":"2021","unstructured":"Low A, et al. Inherited risk of dementia and the progression of cerebral small vessel disease and inflammatory markers in cognitively healthy midlife adults: the PREVENT-Dementia study. Neurobiol Aging. 2021;98:124\u201333.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1915_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neurobiolaging.2012.04.021","volume":"34","author":"A Schuitemaker","year":"2013","unstructured":"Schuitemaker A, et al. Microglial activation in alzheimer\u2019s disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiol Aging. 2013;34(1):128\u201336.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"1915_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"1915_CR18","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, et al. Clinical diagnosis of alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344.","journal-title":"Neurology"},{"issue":"3","key":"1915_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303\u20138.","journal-title":"Arch Neurol"},{"issue":"8","key":"1915_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/jcbfm.2012.59","volume":"32","author":"M Yaqub","year":"2012","unstructured":"Yaqub M, et al. Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[11C]PK11195 brain PET studies. J Cereb Blood Flow Metab. 2012;32(8):1600\u20138.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"4","key":"1915_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neuroimage.2004.10.017","volume":"24","author":"C Svarer","year":"2005","unstructured":"Svarer C, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage. 2005;24(4):969\u201379.","journal-title":"NeuroImage"},{"issue":"5","key":"1915_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/ana.26465","volume":"92","author":"BS Rauchmann","year":"2022","unstructured":"Rauchmann BS, et al. Microglial activation and connectivity in alzheimer disease and aging. Ann Neurol. 2022;92(5):768\u201381.","journal-title":"Ann Neurol"},{"issue":"Pt 7","key":"1915_CR23","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1093\/brain\/awt145","volume":"136","author":"WC Kreisl","year":"2013","unstructured":"Kreisl WC, et al. In vivo radioligand binding to translocator protein correlates with severity of alzheimer\u2019s disease. Brain. 2013;136(Pt 7):2228\u201338.","journal-title":"Brain"},{"issue":"Pt 4","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","volume":"139","author":"L Hamelin","year":"2016","unstructured":"Hamelin L, et al. Early and protective microglial activation in alzheimer\u2019s disease: a prospective study using 18F-DPA-714 PET imaging. Brain. 2016;139(Pt 4):1252\u201364.","journal-title":"Brain"},{"issue":"5","key":"1915_CR25","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/jcbfm.2014.261","volume":"35","author":"SS Golla","year":"2015","unstructured":"Golla SS, et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and alzheimer\u2019s disease patients. J Cereb Blood Flow Metab. 2015;35(5):766\u201372.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"9","key":"1915_CR26","first-page":"2740","volume":"141","author":"M Dani","year":"2018","unstructured":"Dani M, et al. Microglial activation correlates in vivo with both Tau and amyloid in alzheimer\u2019s disease. Brain. 2018;141(9):2740\u201354.","journal-title":"Brain"},{"issue":"6","key":"1915_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00259-013-2359-1","volume":"40","author":"A Varrone","year":"2013","unstructured":"Varrone A, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in alzheimer\u2019s disease patients. Eur J Nucl Med Mol Imaging. 2013;40(6):921\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1915_CR28","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1177\/0271678X17741395","volume":"38","author":"D Knezevic","year":"2018","unstructured":"Knezevic D, et al. Imaging microglial activation and amyloid burden in amnestic mild cognitive impairment. J Cereb Blood Flow Metab. 2018;38(11):1885\u201395.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1915_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neurobiolaging.2016.04.011","volume":"44","author":"WC Kreisl","year":"2016","unstructured":"Kreisl WC, et al. (11)C-PBR28 binding to translocator protein increases with progression of alzheimer\u2019s disease. Neurobiol Aging. 2016;44:53\u201361.","journal-title":"Neurobiol Aging"},{"key":"1915_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.nbd.2018.06.004","volume":"117","author":"P Parbo","year":"2018","unstructured":"Parbo P, et al. Does inflammation precede Tau aggregation in early alzheimer\u2019s disease? A PET study. Neurobiol Dis. 2018;117:211\u20136.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1915_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12974-020-01820-6","volume":"17","author":"R Ismail","year":"2020","unstructured":"Ismail R, et al. The relationships between neuroinflammation, beta-amyloid and Tau deposition in alzheimer\u2019s disease: a longitudinal PET study. J Neuroinflammation. 2020;17(1):151.","journal-title":"J Neuroinflammation"},{"issue":"2","key":"1915_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/alz.12773","volume":"19","author":"RJ Jutten","year":"2023","unstructured":"Jutten RJ, et al. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of alzheimer\u2019s disease. Alzheimers Dement. 2023;19(2):708\u201320.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"1915_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1017\/S1355617720000934","volume":"27","author":"RJ Jutten","year":"2021","unstructured":"Jutten RJ, et al. Identifying sensitive measures of cognitive decline at different clinical stages of alzheimer\u2019s disease. J Int Neuropsychol Soc. 2021;27(5):426\u201338.","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"1915_CR34","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1038\/s41467-023-40937-z","volume":"14","author":"E Nutma","year":"2023","unstructured":"Nutma E, et al. Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases. Nat Commun. 2023;14(1):5247.","journal-title":"Nat Commun"},{"issue":"1","key":"1915_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00401-024-02822-x","volume":"148","author":"EF Garland","year":"2024","unstructured":"Garland EF, et al. The microglial translocator protein (TSPO) in alzheimer\u2019s disease reflects a phagocytic phenotype. Acta Neuropathol. 2024;148(1):62.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1915_CR36","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/brain\/awaf078","volume":"148","author":"SS Wijesinghe","year":"2025","unstructured":"Wijesinghe SS, et al. Post-mortem validation of in vivo TSPO PET as a microglial biomarker. Brain. 2025;148(6):1904\u201310.","journal-title":"Brain"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01915-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01915-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:19:08Z","timestamp":1767068348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01915-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01915-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"type":"electronic","value":"1758-9193"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The historical PET study and Amsterdam Dementia Cohort protocols were both approved by the ethical review board of the VU University Medical Center (2016.061) in accordance with the Declaration of Helsinki [\n                      \n                      ]. Written informed consent was obtained from all patients for the use of their data for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"275"}}